Samrat Pharmachem Limited (SAMRATPH) Share Price
BSE · Basic Materials · Chemicals · ISIN INE103E01016
Key metrics
- Market Cap
- ₹72 Cr
- P/E Ratio
- —
- EPS
- -7.13
- Book Value
- 220.67
- P/B Ratio
- 1.05
- ROE
- -4.86%
- ROCE
- -3.62%
- Debt / Equity
- 0.16
- Net Margin
- -1.14%
- Revenue Growth
- 1.35%
- Profit Growth
- -146.57%
- Dividend Yield
- 0.42%
- 52W High
- ₹333.00
- 52W Low
- ₹190.00
- Market Cap Band
- micro cap
- Face Value
- —
Ratios computed from the annual results period ending 2026-03-31.
About Samrat Pharmachem Limited
Samrat Pharmachem Limited manufactures and sells pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodine, iodine monochloride, iodoquinol, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate and iodide, potassium metaper iodate, povidone iodine, sodium iodate and iodide, and sodium metaper iodate. The company serves the agrochemical, animal feed, chemical, cosmetics, food, pharmaceutical, printing, and textile industries. It also exports its products to the United States, Europe, Africa, Asia, the Middle East, and internationally. Samrat Pharmachem Limited was incorporated in 1992 and is based in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 30
- Promoter Holding
- 59.26%
The full Samrat Pharmachem Limited analysis
Create a free account to open the complete SAMRATPH deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.